STOCK TITAN

Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Rhea-AI Summary

{"summary":"","positive":[],"negative":[],"faq":[]}
Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

+41.92% 16.3x vol
41 alerts
+41.92% News Effect
+38.2% Peak in 7 hr 47 min
+$13M Valuation Impact
$45M Market Cap
16.3x Rel. Volume

On the day this news was published, QNTM gained 41.92%, reflecting a significant positive market reaction. Argus tracked a peak move of +38.2% during that session. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $13M to the company's valuation, bringing the market cap to $45M at that time. Trading volume was exceptionally heavy at 16.3x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Lawsuit amount: USD $700 million Series length: 3-part series
2 metrics
Lawsuit amount USD $700 million Claim in lawsuit against CIBC and RBC
Series length 3-part series CTV W5 investigative program on Quantum BioPharma

Market Reality Check

Price: $3.64 Vol: Volume 78,267 vs 20-day a...
low vol
$3.64 Last Close
Volume Volume 78,267 vs 20-day average 169,177 (relative volume 0.46) suggests subdued trading into this headline. low
Technical Price $9.84 is trading below the 200-day MA $13.71, reflecting a weaker intermediate trend before this news.

Peers on Argus

Key biotech peers like MNOV, ABVC, APLT, DTIL and PMVP all showed negative moves...

Key biotech peers like MNOV, ABVC, APLT, DTIL and PMVP all showed negative moves (e.g., -1.31%, -0.44%, -1.77%, -2.19%, -0.79%), while QNTM’s pre-news move of -0.19% was smaller, indicating more stock-specific dynamics.

Historical Context

5 past events · Latest: Dec 10 (Neutral)
Pattern 5 events
Date Event Sentiment Move Catalyst
Dec 10 Private placement Neutral -0.2% Non-brokered private placement and ATM termination with modest negative move.
Dec 01 Lawsuit media segment Neutral -11.7% Final W5 segment on USD $700M lawsuit linked to double-digit decline.
Nov 28 Lawsuit media segment Neutral -15.0% Repeat W5 Part 2 airing on alleged manipulation with sharp negative move.
Nov 27 Lawsuit media segment Neutral -15.0% W5 Part 2 coverage of alleged manipulation linked to steep selloff.
Nov 26 Lawsuit media launch Neutral +41.9% Initial W5 three-part series announcement with strong positive price reaction.
Pattern Detected

Recent history shows sharp volatility tied to W5 coverage of the USD $700 million lawsuit: an initial large upside reaction followed by significant negative moves on subsequent segments and later mild pressure around a private placement.

Recent Company History

Over the last few weeks, Quantum BioPharma’s news flow centered on its USD $700 million market-manipulation lawsuit and related W5 coverage. The initial Nov 26 W5 feature coincided with a 41.92% gain, while Parts 2 and the final segment on Nov 27–28 and Dec 1 saw declines of -14.99% and -11.65%. A Dec 10 private placement and ATM termination then paired with a modest -0.19% move, underscoring ongoing legal and financing overhangs.

Market Pulse Summary

The stock surged +41.9% in the session following this news. A strong positive reaction aligns with p...
Analysis

The stock surged +41.9% in the session following this news. A strong positive reaction aligns with prior trading around W5 coverage, where the initial Nov 26 segment coincided with a 41.92% gain. The news again spotlights the USD $700 million lawsuit and alleged “stock spoofing,” a theme already linked to sharp moves. However, past follow-up segments saw double-digit declines, underscoring that media-driven spikes have historically been volatile and vulnerable to reversal as attention normalizes.

Key Terms

stock spoofing, market manipulation, multiple sclerosis
3 terms
stock spoofing financial
"The series explores the phenomenon of “stock spoofing,” a market manipulation tactic..."
Stock spoofing is a deceptive trading tactic where someone places large buy or sell orders they intend to cancel, creating a false impression of demand or supply to push the price in a useful direction and then trades against that fake pressure. Think of it as faking a long line outside a shop to lure customers inside; for investors, spoofing can distort quoted prices, create sudden swings, and lead to unexpected losses or reduced trust in market fairness.
market manipulation financial
"the company’s allegations of stock market manipulation."
Market manipulation is when individuals or groups deliberately distort the price or supply of a security by using deceptive or artificial tactics — for example spreading false information, placing fake orders, or coordinating trades to create a false appearance of demand. It matters to investors because it can make prices unreliable, hide real risk or value, and cause sudden losses when the manipulation stops, much like someone rigging an auction to make a bid look more valuable than it really is.
multiple sclerosis medical
"company’s multiple sclerosis research nearly derailed by ‘market manipulation’?"
A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.

AI-generated analysis. Not financial advice.

TORONTO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 will air, starting today, a three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation.

Top CTV News journalist and W5 investigative reporter Jon Woodward describes Part One of the series in an article entitled, “Was a Canadian company’s multiple sclerosis research nearly derailed by ‘market manipulation’?” The series explores the phenomenon of “stock spoofing,” a market manipulation tactic that is illegal in both Canada and the United States, and the basis of a USD $700 million lawsuit by Quantum Biopharma against two of Canada’s largest banks CIBC and RBC.

The first of three parts of the W5 investigative series can be viewed today on CTV News at: W5: MS research derailed by stock market spoofing: lawsuit

Quantum BioPharma Chief Executive Officer Zeeshan Saeed commented, “We thank W5 for their important investigation into the illegal, but little known, practice of stock spoofing and some of its harmful effects on retail investors. Our goal has always been to bring Lucid-MS – a potentially game-changing drug that in animal studies has been shown to stop and even reverse the degradation of nerve cells (a hallmark of multiple sclerosis) giving back mobility and control to the body unlike any drug today for the benefit of millions of people around the world who courageously live with this progressive and debilitating disease. By shining a light on our experience with alleged stock market manipulation, we hope to prevent other companies, their shareholders and their beneficiaries, from experiencing what we have been through.”

For more information visit: www.quantumbiopharma.com

About Quantum BioPharma Ltd.

Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 19.86% as of September 30, 2025 of Unbuzzd Wellness Inc. at www.unbuzzd.com. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information visit www.quantumbiopharma.com.

Forward-Looking Information

This press release contains certain "forward-looking statements" within the meaning of applicable securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as “believes”, “hopes”, “alleges”, “pending”, “further”, or variations of such words and phrases or statements that certain actions events or results “may”, “could”, “which”, or “will” and similar expressions) are not statements of historical fact and may be forward-looking statements. Forward-looking information herein includes, but is not limited to, statements regarding: the Company’s ongoing litigation against major financial institutions; the potential outcome or judgment value; expectations regarding whistleblower submissions and related rewards; continued market integrity initiatives; future business performance and possible acquisitions.

In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation: the ability to obtain and validate whistleblower evidence; the timing and outcome of legal proceedings; resolution of ongoing litigation on favourable terms, availability and sufficiency of litigation funding; continued regulatory compliance and market stability for the Company’s operations.

The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the adverse outcome of legal actions; the receipt and credibility of whistleblower disclosures; changes in applicable laws and regulations; the actions of third parties involved in alleged manipulation; evolving market dynamics; the sufficiency of future litigation proceeds to fund the Company’s whistleblower reward; the continued ability to obtain sufficient litigation funding; limited future growth opportunities, and reliance on key personnel.

Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change.

The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the SEC's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

Contacts:

Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811

Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com


Quantum BioPharma Ltd

NASDAQ:QNTM

QNTM Rankings

QNTM Latest News

QNTM Latest SEC Filings

QNTM Stock Data

13.99M
3.50M
10.75%
30.71%
1.27%
Biotechnology
Healthcare
Link
Canada
Toronto